The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB

• Autors principals: Shike Lou (Autor), Zhujun Cao (Autor), Wanqing Chi (Autor), Xiaoyin Wang (Autor), Mingyang Feng (Autor), Lanyi Lin (Autor), Yezhou Ding (Autor), Kehui Liu (Autor), Lihong Qu (Autor), Gangde Zhao (Autor), Shisan Bao (Autor), Hui Wang (Autor)
• Format: Llibre
• Publicat: Frontiers Media S.A., 2023-04-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Aim: To analyze the safety of immune checkpoint inhibitors in primary liver cancer patients and to identify the risk factors for immune-related adverse events (irAEs).Methods: The study enrolled 106 patients with primary liver cancer, including 81 with hepatocellular carcinoma and 25 with intrahepat...